Abstract 5147
Background
Patient rights has been developed from human rights. Human rights emerged from the Universal Declaration of Human Rights. The Declaration is a milestone document in the history of human rights (1). Today the patient’s rights have become an important issue on the political agenda. Individual’s awareness of their own rights in the health area is constantly increasing. Patient’s rights are becoming primary concern in improving quality of health care (2). Today the patient becomes the consumer (3). The most important role that nurses have is delivering quality care for the patients and also act as patient advocates. Nurses must understand the importance of patient rights. The main aim of the survey is to analyze, investigate, compare and present, the legal framework of the patient’s rights legislation in the European Union.
Methods
A literature search and review related to the patient right was conducted using PubMed, Cinahl, Medline and Google Scholar. With descriptive method we set up a theoretical framework of the patient’s rights legislation. We also use comporative method to discover the similarities and differences between legal systems and their components.
Results
Patient’s rights are in thirteen European Member States regulated by specific law - Law on patient’s rights.
Conclusions
EU Member States do not have a common legislation for patient’s rights. Patient’s rights vary from country to country. Some countries have a single law or act, others use multiple pieces of legislation. Nurses are an important voice of the patient. References: 1. Universal Declaration of Human Rights. Avalible at: Https://www.un.org/en/universal-declaration-human-rights/ (10. 4. 2019). 2. Opinion of the European Economic and Social Committee on Patients’ rights. Official Journal EU, C10/67. Avalible at: Https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:010:0067:0071:EN:PDF (10. 4. 2019). 3. OECD - Patients, Patient Organisations and the Production of Medical Science and Technology. Avalible at: Http://www.oecd.org/education/innovation-education/32126031.pdf (10. 4. 2019). 4. Kozuh M., 2016. Legal Arrangements for the Protection of Patients’ Rights: A Comparative Overview of the Regulation in the EU (Master Thesis). University of Primorska Slovenia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Maja Kozuh.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract